NCT05091723View on ClinicalTrials.gov

TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental Oxygenation

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 13, 2021

Primary Completion Date

November 24, 2021

Study Completion Date

November 24, 2021

Conditions
Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19)
Interventions
DRUG

Nezulcitinib (TD-0903) Dose A

TD-0903 Dose A

DRUG

Nezulcitinib (TD-0903) Dose B

TD-0903 Dose B

Trial Locations (1)

90630

Theravance Biopharma Investigational Site, Cypress

Sponsors
All Listed Sponsors
lead

Theravance Biopharma

INDUSTRY

NCT05091723 - TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental Oxygenation | Biotech Hunter | Biotech Hunter